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Abstract
The purpose of the present study is to estimate the current incidence of febrile events (FEs) and infectious episodes in acute
lymphoblastic leukemia (ALL) and evaluate the outcome. We analyzed data on all FEs in a cohort of patients affected by ALL
admitted to 20 Italian hematologic centers during 21months of observation fromApril 1, 2012 to December 31, 2013. Data about
treatment phase, steroids, neutropenia, type and site of infection, and outcome of infection were collected. The population
comprehended 271 ALL adult patients. Median age was 46 years old (range 19–75), M/F 1.1:1. We collected 179 FEs occurring
during 395 different phases of treatment in 127 patients (45.3% incidence): remission induction treatment 53.1%, consolidation/
maintenance 35.7%, treatment for a first or second relapse 44.3%, and refractory disease 85.7%. The incidence of FUO (fever of
unknown origin) was 55/395 (13.9%). In the remaining cases, bacteria caused 92 FEs (23.2%), fungi 17 (4.3%), viruses 5 (1%).
Mixed infections occurred in 10 cases mainly fungal+bacterial (9/10 cases). Neutropenia was mostly present at onset of FE
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(89.9% of FEs). Mortality rate was 11.7% (21/179) while 16 deaths occurred with evidence of infection (8.9%). Age > 60 years,
neutropenia, poor performance status, steroids, refractory disease, and mixed infections significantly correlated with infection-
related mortality. A statistically significant association with mortality was observed also for pulmonary localization and bacter-
emia. Our study describes the real-life epidemiological scenario of infections in ALL and identifies a subset of patients who are at
higher risk for infection-related mortality.
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Introduction
Febrile events (FEs) and infectious complications often make
hematologic malignancies difficult to treat.
Several studies have defined the diseases and phases of
treatment at higher risk for infection [1–6]. Infectious risk in
acute lymphoblastic leukemia (ALL) has always been consid-
ered low but current epidemiology of FEs in such patients is
not yet well elucidated. Most data regarding infections are
derived from case reports or studies of specific subpopulations
of ALL patients or pathogens (pediatric patients’ cohorts, in-
cidence after specific treatments) [7–13]. Moreover, bone
marrow involvement and chemotherapy-associated toxicities
contribute to infection risks associated with ALL. Particularly,
higher doses of anthracycline and antimetabolite-based che-
motherapy regimens are now frequently administered for lon-
ger periods. Steroids are also a cornerstone of the treatment of
lymphoproliferative diseases, but have pleiotropic cumulative
immunosuppressive and catabolic effects. Therefore,
infection-related risks in the ALL population relative to other
high-risk malignancies may be underestimated.
The aim of the present study was to investigate the current
incidence of FEs and the infectious risk in ALL patients and to
evaluate the outcome of such complications.
Patients and methods
Data collection
We prospectively collected data about FEs occurring in ALL
patients in any phase of disease followed in Italian hematolo-
gy centers participating to the study within the SEIFEM
(Sorveglianza Epidemiologica Infezioni Fungine in
EMatologia) group from April 1, 2012 until December 31,
2013. The study was approved by the ethics committee of
each center. Case report forms were compiled and data
concerning hematologic risk (immunophenotype, white blood
cell count, cytogenetics, karyotype), treatment (phase of dis-
ease, chemotherapy regimen, previous hematopoietic stem
cell transplant procedures), risk factors for infection (neutro-
penia, placement of CVC, positive surveillance swabs, use of
antimicrobial prophylaxis and steroids, presence of
comorbidities), characteristics of FE (signs and symptoms,
etiology, radiologic abnormalities, treatment of infection)
were analyzed. Patients that developed FEs during hematopoi-
etic stem cell transplantation (HSCT) procedures (autologous
or allogeneic) were withdrawn from the study so as not to bias
the results as these practices are recognized as a higher risk for
infectious complications. Similarly, patients receiving
tyrosine-kinase inhibitors (TKI) monotherapy were excluded.
Informed consent was obtained from all individual partici-
pants included in the study.
All the patients were treated according to NILG 10/07 [14]
or GIMEMAprotocols for ALL [15]. GMALL protocols were
also used for T lineage ALL [16].
The diagnostic work-up at onset of fever did not signifi-
cantly differ among the centers and included the use of micro-
biological data, CT scans, X-rays, bronchoalveolar lavage,
and histological examination.
The outcome of infection was evaluated at 30 days from the
first fever onset.
Definitions
Performance status (PS) was graded according to the Eastern
Cooperative Oncology Group Scale [17].
Neutropenia was defined as an absolute neutrophil count <
500 cells/mm3 or < 1000 cells/mm3 with a prediction of de-
cline to < 500 cells/mm3.
Fever was defined according to IDSA guidelines as a single
increase of blood temperature to 38.3 °C or either ≥ 38 °C for
1 h or more [18]. Hypothermia (< 35 °C) was considered as
possible sign of infection and thus investigated.
Fever of unknown origin (FUO) was described when
fever occurred in the absence of a specific infectious fo-
cus detected by physical, radiological, or microbiological
examination.
Bloodstream infections (BSI) were defined by the presence
of one or more positive blood cultures together with clinical
signs. In case of skin contaminants, a minimum of two posi-
tive blood cultures was necessary. When the pathogen was
only traced in blood, we defined it primarily (e.g., catheter-
related BSI included). Secondary BSI was defined as the de-
tection in bloodstream of an organism causing infection in
another body site.
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Invasive fungal infections were defined according to the
European Organization for Research and Treatment of
Cancer/Mycoses Study Group (MSG) [19].
Steroid treatment was identified with administration of
prednisone/prednisolone for at least 10 days at a dosage of
25 mg minimum (or equivalent dosage).
We considered mortality due to infection when patients
died with clinical evidence and/or microbiological signs of
infection.
Statistical analysis
Number and percentage were calculated for demographic da-
ta, FEs, treatment data and for characteristics of patient at FE
onset.
Number and percentage of FEs and related deaths were
reported by identified agent and by phase of treatment.
Univariate and multivariable logistic regression were used
to investigate the association between death and patient risk
factors. A multivariate logistic regression model was used to
explore independent risk factors for infection-associated mor-
tality. Risk factors associated with mortality were reported as
odds ratios (ORs) and 95% confidence intervals (CIs).
Statistical analysis was carried out using SAS software (ver-
sion 9.2; SAS Institute, Milan, Italy). A two-sided P value of
less than 0.05 was considered statistically significant.
Results
Characteristics of patients and distribution of FEs
Over the observation period, 20 Italian participating centers
enrolled all patients diagnosed with ALL at any phase of dis-
ease, except HSCT procedures.We screened 271 patients. The
population was predominately male (51.1%) with a median
age of 46 years (range 19–75). A total of 395 treatment phases
were recorded in the 271 patients. The characteristics of the
127 patients that developed a FE are shown in Table 1.
We registered 179 FEs with an incidence of 45.3% (179/
395). The distribution per phase of treatment was the follow-
ing: 53.1% (84/158) during remission induction treatment,
35.7% during consolidation/maintenance (54/151), 44.3%
during treatment for a first or second relapse (35/79), and
85.7% for refractory disease (6/7).
FEs occurred after a median of 7 days after the end of
chemotherapy (range 1–100) and mostly during neutropenia
[61, 89.9%—on average after 6 days (range 1–28)]. A CVC
was placed in 140 cases (78.2%). Patients were receiving cor-
ticosteroids in 123 cases (68.7%) of FEs. The distribution of
different type of FEs per phase of treatment is shown in
Table 2. As shown, the incidence did not differ significantly
during the different phases of treatment except for fungal and
mixed infections.
Fever of unknown origin
The incidence of FUO was 13.9% (55/395), representing
30.7% of all FEs and did not differ significantly according
to phase of treatment from 15.8% (25/158) at remission in-
duction, 13.9% (21/151) during consolidation/maintenance,
10.1% (8/79) during relapse, and 14.2% (1/7) during refracto-
ry disease.
Bacterial infections
Quinolone antibiotic prophylaxis was administered in 44.6%
of FEs.
Table 1 Demographic characteristics of patients (n = 127)
No. (%)
Male sex/female sex 65/62 (51.1/48.9)




Philadelphia chromosome 29 (22.8)
Characteristics of patients presenting
FEs, n = 179 total, no (%)
Phase of treatment
• Induction 84 (46.9)
• Consolidation/maintenance 54 (30.2)
• Relapse/refractory 41(22.9)
Conventional chemotherapy 159 (88.8)
Conventional chemotherapy+TKI 20 (11.2)
Characteristics of patients at FE onset,
n = 179 FEs, no (%)
Hypercytemia (WBC > 30.000) 59 (32.9)
CNS or other sanctuary site 17 (9.49)
HEPA filters rooms 91 (50.8)
Previous allogeneic HSCT 6 (3.3)
Neutropenia (PMN < 500) 161 (89.9)







Other (NASH**, non-viral hepatitis) 12 (6.7)
*Chronic renal insufficiency
**Non-alcoholic steatosis hepatitis
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The incidence of bacterial infections according to phase of
treatment was 27.8% (44/158) during remission induction,
18.5% (28/151) during consolidation/maintenance, 22.7%
(18/79) during relapse, and 28.5% (2/7) during refractory
disease.
For FEs with a bacterial etiology, 77 microbiologically
proven bacterial infections were registered during 395 phases
of treatment, with an overall incidence of 19.4%. The inci-
dence was 22% if mixed bacterial infections are included;
bacteria were thus involved in 48.6% of all FEs.
Most documented infections presented as a primary blood-
stream infections (61/77, 79.3%), followed by 5 primary
pneumonias (5/77, 6.4%), 7 (7/77, 9.1%) infections of geni-
tourinary tract, and 4 (4/77, 5.2%) infections of gastro-
intestinal tract.
In 59 cases, FEs were caused by a single bacterium, pre-
dominantly Gram-negative (38/59, 64.4%). In 18 cases of
bacterial FEs, two or more bacteria were isolated. Both
Gram-positive and Gram-negative pathogens were isolates
in 12 cases, whereas two of more Gram negative were isolates
in 5 cases, and one patient had two Gram-positive species.
No clinical or radiological signs of infection or isolate were
recovered in 15 FEs. Because these FEs responded to empiric
antimicrobial treatment, we classified these cases as clinically
documented infection, with possible bacterial origin.
Fungal infections
Seventeen cases of invasive fungal disease (IFD) were ob-
served during 395 cycles of treatment (4.3% overall inci-
dence). When EORTC/MSG standardized diagnostic criteria
are applied, 6 cases (35.3% IFDs) were proven, 8 cases
(47.1%) were probable IFD, and 3 cases (17.6%) were possi-
ble IFD. As for the proven/probable IFDs, moldswere isolated
in 9 cases (all Aspergillus spp, 2.2%), while yeasts were iso-
lated in 5 cases (all Candida spp, 1%). Molds caused 8 cases
of pneumonia and one case of sino-nasal infection, while
yeasts were associated with three episodes of candidemia
and two cases of chronic disseminated candidiasis.
Co-infections were present in 10 IFD episodes, including 9
cases with bacteria, and 1 case with both bacteria and virus.
Considering these mixed infections, the combined incidence
of fungal infection was 6.8%.
Antifungal prophylaxis during remission induction chemo-
therapy was employed in 37 cases (in 4 cases with
posaconazole, in 1 case with itraconazole, in 19 cases with
fluconazole, in 13 cases with liposomal amphotericin B).
Prophylaxis against P. jiroveciiwas used in 32.9% of patients.
The IFD incidence per phase of treatment was 5.6% for
induction phase (9/158), 5.1% for relapse phase (4/79), 1.3%
(2/151) for consolidation/maintenance, and 28.5% (2/7) for
refractory disease.
Viral infections
We registered four viral infections (incidence 1%). One pa-
tient developed viral infections during induction remission
treatment, and three patients during consolidation/mainte-
nance. Cytomegalovirus was detected by polymerase chain
reaction (PCR) in 3 cases andH1N1 in one case. In 50% cases,
the patient had received antiviral prophylaxis with acyclovir
or valacyclovir.
Mixed infections
Mixed infections occurred in 10 cases (incidence of 2.5%).
Bacterial+fungal infections were the most common (9 cases)
with a predominance of Gram-negatives (8/10). Bacterial+
fungal+viral infection occurred in 1 case. In 5 cases, the pa-
tient had a relapsing disease, in 4 cases underwent remission
induction treatment and in1 case during refractory disease.
Mortality
We evaluated mortality within 30 days from the onset of FE.
Twenty-one deaths occurred of which 16/21 (76.1%) with
evidence of infection (Table 3). The overall mortality rate
was 7.7% (21/271). The mortality rate in FE population was
12.5% (16/127). Considering febrile events, an unfavorable
outcome occurred in 8.9% cases (16/179) (death Bwith
infection^).
The highest rates of infection-associated mortality occurred
in patients with refractory ALL (50%) with mixed infection
(30%) (Table 3). Mortality rates did not significantly differ
between patients with Gram-positive versus Gram-negative
infections.
Table 2 Microbiologically documented infections according to phase of treatment
Phases of treatment (no. febrile episodes) Bacterial (%) Fungal (%) Viral (%) Mixed (%) FUO (%)
Induction (84/158) 44 (27.8) 9 (5.6) 2 (1.2) 4 (2.5) 25 (15.8)
Consolidation/maintenance (54/151) 28 (18.5) 2 (1.3) 3 (1.9) / 21 (13.9)
Relapse (35/79) 18 (22.7) 4 (5.1) / 5 (6.3) 8 (10.1)
Refractory (6/7) 2 (28.5) 2 (28.5) / 1 (14.2) 1 (14.2)
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Risk factors for mortality
In univariate logistic regression age (p = 0.0056), the presence
of CNS involvement at diagnosis of ALL (p = 0.0015), ECOG
score > 1 at FE onset (p = 0.02), uncontrolled disease (p ≤
0.001), and mixed infection (p = 0.0001) were significantly
associated with death (Table 4). On the contrary, a disease
during first induction (p = 0.006) or in remission (p = 0.02)
were associated with reduced odds of death.
Results were confirmed in multivariable analysis adjusted
for patient age. Specifically, the presence of CNS/sanctuary
site at the time of ALL diagnosis (OR 4.05, 3.31–4.96;
p < 0.001), relapse or refractory ALL (OR 11.92, 9.27–
15.32; p < 0.001), mixed infection (OR 3.87, 2.99–5.00,
p < 0.001), pneumonia (OR 1.96, 1.62–2.36, p < 0.001), and
possible exposure to high-dose steroids (OR 3.39, 2.77–4.16;
p < 0.001) were associated with overall mortality. On the other
hand, infection at the time of first induction chemotherapywas
associated with a lower risk of death (OR 0.76, 95% CI 0.58–
0.99, p = 0.04).
Deep and prolonged neutropenia prior to infection diagno-
sis was associated with an exponential risk of predicted prob-
ability of death, especially after 20 consecutive days (Fig. 1).
A separate logistic regressionwas also conducted for the 18
deaths occurred in the presence of infection. Univariate anal-
ysis confirmed the significance for age (p < 0.001), use of
steroids (< 0.001), bacteremia (p < 0.001), and pneumonia
(p < 0.001). A better PS was found protective (ECOG score
< 1 a FE onset, p < 0.001).
Discussion
Hematologic malignancies are often burdened with infectious
complications. In recent years, several studies have been con-
ducted to estimate these events. However, they often concen-
trate on specific pathogens (e.g., bacteremia or fungal
Table 3 Mortality with evidence of infection (16 pts)





Mixed infections 3/10 (30.0)
FUO 2/55 (3.6)
Phase of treatment
Remission induction treatment 4/84 (4.7)
Consolidation/maintenance 2/54 (3.7)
Relapse 7/35 (20.0)
Refractory disease 3/6 (50.0)
Table 4 Risk factors for overall mortality (univariate and multivariable analysis)
Variable Univariate analysis Multivariate analysisa
OR (95% CI) p value OR (95% CI) p value
Age (≥ 60) 3.63 (1.21–10.43) 0.0056 10.18 (8.11–12.78) < 0.001
Lineage (B vs T) 0.95 (0.28–4.19) 0.93
PH chromosome 1.33 (0.35–4.20) 0.60
CNS/sanctuaries involvement at ALL diagnosis 5.34 (1.39–18.41) 0.0015 4.05 (3.31–4.96) < 0.001
ECOG (2–4 vs 0–1) 2.85 (1.01–8.02) 0.02
First induction 0.22 (0.05–0.75) 0.006 0.76 (0.58–0.99) 0.04
Consolidation/maintenance 0.21 (0.02–0.95) 0.02
Relapse/refractory 12.69 (4.10–42.94) < 0.0001 11.92 (9.27–15.32) < 0.001
Steroids 2.08 (0.63–8.91) 0.19 3.39 (2.77–4.16) < 0.001
CVC 0.87 (0.28–3.28) 0.81
FUO 0.33 (0.06–1.24) 0.08
Clinically documented infection 0.47 (0.01–3.45) 0.47
Bacterial infection 0.79 (0.26–2.20) 0.62
Fungal infection 1.71 (0.28–7.01) 0.42
Viral infection 2.58 (0.04–33.74) 0.40
Mixed infection 9.56 (1.93–45.50) 0.0001 3.87 (2.99–5.00) < 0.001
Pneumonia (primary site and/or secondary) 2.16 (0.71–6.14) 0.10 1.96 (1.62–2.36) < 0.001
Bacteremia (primary site and/or secondary) 1.57 (0.56–4.39) 0.32
a Adjusted for age
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infections) or regard specific malignancies and treatment
courses (e.g. acute myeloid leukemia during remission induc-
tion, HSCT) known to be at higher risk for infection [2, 5,
20–25]. Investigations concerning acute lymphoproliferative
disorders are acquiring interest but remain still scarce [26].
In 2004, Offidani et al. retrospectively described the epide-
miology of infectious complications in adult ALL patients in a
monocentric experience [27]. However, the incidence and na-
ture of such events might have changed in the recent years;
therefore, our purpose was to describe the current incidence
and outcome of infectious complications in ALL in a large
cohort that included different phases and types of treatment
and to define a risk profile for these patients. The strength of
our study is that all patients were enrolled and followed pro-
spectively during the same time period. We purposely exclud-
ed FEs occurring in ALL patients undergoing HSCT (autolo-
gous/allogeneic) to obtain a clearer picture of infection risk
specific to ALL and its management. Infection risk in the ALL
patients following HSCT is dominated by transplant related
factors such as graft versus host disease (GVHD) involving
the GI tract and prolonged marrow aplasia [28, 29]. On this
basis, the impact of infectious agents may be higher during
such procedure [30, 31]. Likewise, patients receiving TKI
monotherapy were excluded in order not to bias our results.
To our knowledge, data about the incidence of FEs in dif-
ferent phases of treatment for ALL have not yet been eluci-
dated. The previous HEMA chart study reported an incidence
of febrile events during remission induction treatment for
ALL of 32.6% [1]. In our cohort, the incidence during induc-
tion treatment was 53.1% and was similar during re-induction
for relapsed patients (44.3%). As expected, refractory patients
had the highest incidence of FEs (85.7%), whereas patients in
complete remission the lowest (35.7%). However, this quite
noteworthy rate, if compared to the one observed in acute
myeloid leukemia during consolidation/maintenance, could
be explained considering the highly aggressive chemotherapy
regimens even during consolidation or maintenance that are
currently used for ALL.
Despite the most improved diagnostic procedures, FUO
represents a considerable part of FEs in the population in
study. There is still controversy if FUO are undetected in-
fectious episodes or phenomena related to the hematologic
malignancy or to its treatment. Given the pathophysiology
of ALL that is characterized by a notable inflammatory bur-
den, FUOs may be related to ALL itself and/or it could
represent treatment-related fever. In any case, mortality
rates registered during FUO were low (3.6%). Probably
prompt empiric prescription of anti-infective drugs at fever
onset might play a role in the reduction of mortality rates for
FE misdiagnosed as FUO that are actually sustained by mi-
croorganisms. In our cohort, more than one third of FEs with
a microbiological diagnosis was caused by bacteria (about
74% of the non-FUO events). Gram-negative bacteria
accounted for the majority of documented infections, as
opposed the predominance of Gram-positive pathogens re-
ported in epidemiological studies published in the 1990s
and early 2000 [32, 33]. However, no difference in terms
of mortality was found. In fact, bacterial infections seem to
have little impact on overall and infection mortality, as com-
pared to IFI and mixed infections. The overall scarce utili-
zation of quinolones prophylaxis may be supported by the
short period of neutropenia that patients undergo during
consolidation/maintenance therapy. In fact, the wider use
was made during remission induction treatment. In the
GRAAL group experience, the incidence of bacterial infec-
tions during remission induction treatment was slightly
higher, with a predominance of Gram-positive bacteria.
This might reflect the different local epidemiology as in
Italy an increase of multiresistant Gram-negative bacteria
has been observed. However, mortality rates were analo-
gous [34].
The incidence of IFD was 4.3% (9.4% of FE) apparently
in reduction compared to other previous studies [21] and
from the one recently published by Mariette and colleagues
(6.7%) [35] and comparable to the recent study by Nicolato
et al [36]. However, our study included patients in different
treatment phases of ALL, including phases at lower risk for
infection (i.e., consolidation/maintenance). As expected,
the latter was the category that presented the lowest inci-
dence (Table 2). Mold infections were more common than
yeast. Other species were found in the contest of mixed
infections. The mold/yeast ratio was 1.8:1. Candida BSI
infections were still evident in our study cohort (incidence
Fig. 1 Relationship between probability of all-cause mortality and
duration of severe neutropenia prior to infection. The solid line
represents the probability estimate death = exp(− 2.640 + 0.0809 × days
PMN < 500)/(1 + exp(− 2.640 + 0.0809 × days PMN < 500)). Dashed
lines are the 95% confidence intervals. Bars represent the number of
patients per duration of neutropenia before infection
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0.7%) but were lower than those reported in previous stud-
ies by the SEIFEM group [23].
Viral infections rates were low (incidence 1%, 2.7% of all
FEs) but probably underestimated in our study. Subclinical
viral infections are common and may be overshadowed by
bacterial or fungal disease in some patients. However, mor-
tality rates were relatively high among patients who had a
microbiologically documented viral infection (Table 3).
Mixed infections caused primarily by bacteria and fungi
accounted for 5.5% of all FEs. The presence of mixed infec-
tions likely reflects mucosal damage observed in leukemia
patients undergoing chemotherapy. Mixed infections were al-
so responsible for the highest mortality rates.
Mortality rates for/with infection were low compared to
other hematologic malignancies, but still notable.
Apparently, deaths caused by fungal infections and mixed
infections are more frequent than in previous studies by the
SEIFEM group [1]. This may be due to the chemotherapy
regimens administered, as they are increasingly aggressive
and prolonged. Conversely, deaths by FUO are lowering
probably as a result of improved diagnostic procedures.
Beyond IFDs, other risk factors for mortality seem to be,
as expected, an uncontrolled malignancy, older age (>
60 years old) and poor PS. However, the main role is played
by neutropenia. In fact, during almost every FE (89.9%), the
patient had neutrophil count lower than 500/mm3 and all the
deceased patients were neutropenic. Previous studies dem-
onstrated the correlation with the depth and duration of neu-
tropenia with the incidence of infections [37]. In our inves-
tigation, deeper and more prolonged neutropenia is associ-
ated with a higher risk of predicted probability of death.
Steroid use is another distinct risk factor for mortality. In
fact, a large use of steroids during all the treatment of ALL
(also to contain refractory disease) is observed. Moreover,
concomitant presence of pneumonia should be carefully
considered in FE ALL patients. CNS localization at diagno-
sis of ALL does not seem to decisively affect the outcome in
presence of infection but seems significant in the context of
overall mortality.
In conclusion, our study illustrates the current inci-
dence of fever and infectious complications in a disease
formerly considered at low risk. The phases of treatment
in which infectious episodes are more frequent are first
induction/reinduction treatment and even higher in pa-
tients with refractory disease. Most microbiologically doc-
umented FEs in ALL patients were caused by bacteria;
however, the incidence of IFD (4.3%) is sufficiently high
to justify intensive diagnostic workup for fungal patho-
gens including molds during fever. Remarkably, mixed
infections, often involving fungi, are the most concerning.
Primitive or secondary pulmonary localization seems to
be critical, together with bacteremia, as poor prognostic
factor, as well as use of steroids and neutropenia. A poor
PS also appears prominent in the management of FEs in
ALL. Together with steroid use, an uncontrolled malig-
nancy and a poor PS seem to be crucial for mortality with
evidence of infection.
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